Compare Amgen, Inc. (AMGN) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs KB Financial Group, Inc. — how do they compare? Amgen, Inc. trades at $417 (market cap $224.14B), while KB Financial Group, Inc. trades at $117.99 (market cap $41.21B). The key difference: Amgen, Inc. is far larger — about 5.4× KB Financial Group, Inc.'s market cap, and KB Financial Group, Inc. pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| AMGN | KB | |
|---|---|---|
Market Cap | $224.14B | $41.21B |
Sector | Health | Financials |
52-Week High | $417.20 | $124.01 |
52-Week Low | $271.18 | $77.50 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
KB Financial trades at $117.63, down 2.57% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and rising revenue ($21.23T in 2025). Valuation metrics appear attractive with a P/E of 10.36 and P/B below 1. Recent news highlights momentum and dividend potential, while cash flow trends show volatility with a net inflow of $4.41T in 2025.
The outlook remains positive given earnings momentum and diversification into non-banking segments (43% of earnings). Risks include volatile cash flows and macroeconomic sensitivity. Analysts are mixed (33% Buy, 67% Hold), suggesting cautious optimism. The stock's current price near support at $117 offers a potential entry, but investors should monitor execution on non-banking targets and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
